2026-02-28 02:50Company and Industry Summary Company: 百济神州 (BeiGene) Key Financial Performance - Total revenue for 2025 reached $5.34 billion, representing a 40.2% increase year-over-year [1] - Product revenue for 2025 was $5.28 billion, up 39.8% compared to the previous year [1] - Net profit for 2025 was $290 million, a significant recovery from a net loss of $640 million in the same period last year [1] - Q4 2025 revenue was $1.5 billion, reflecting a 32.8% year-over-year increase and a 6.1% quarter-over-quarter increase [1] - Q4 2025 product revenue was $1.48 billion, up 32.1% year-over-year and 5.8% quarter-over-quarter [1] - Q4 2025 net profit was $66 million, compared to a net loss of $150 million in the same quarter last year [1] Product Performance - Revenue from the drug Tislelizumab for 2025 was $740 million, an 18.8% increase year-over-year [1] - Q4 2025 revenue for Tislelizumab was $180 million, an 18.3% increase year-over-year but a 4.5% decrease quarter-over-quarter [1] Company: 其他药品 (Other Drugs) Key Financial Performance - Revenue from the drug Zebrutinib for 2025 was $3.93 billion, a 48.6% increase year-over-year [2] - Breakdown of Zebrutinib revenue: - United States: $2.83 billion (+45.1%) - Europe: $600 million (+66.2%) - China: $340 million (+33.3%) - Rest of the World (ROW): $160 million (+105.8%) [2] - Q4 2025 revenue for Zebrutinib was $1.15 billion, a 38.4% increase year-over-year and a 10.1% increase quarter-over-quarter [2] - Q4 2025 revenue breakdown for Zebrutinib: - United States: $840 million (+37.1%, +14.4% QoQ) - Europe: $170 million (+47.2%, +2.2% QoQ) - China: $90 million (+26.0%, -5.5% QoQ) - ROW: $160 million (+61.0%, +1.8% QoQ) [2] Other Drug Revenues - XGEVA revenue for 2025 was $310 million (+36.4%), with Q4 revenue of $70 million (+12%, -16.9% QoQ) [2] - BLINCYTO revenue for 2025 was $100 million (+40.2%), with Q4 revenue of $24 million (+17.6%, -20.4% QoQ) [2] Cost and Profitability Metrics - Product gross margin for 2025 was 87.3%, an increase of 3 percentage points [2] - Selling and administrative expense ratio was 39.0%, a decrease of 9.1 percentage points [2] - R&D expense ratio was 40.2%, a decrease of 11.1 percentage points [2] - Q4 2025 product gross margin improved to 90.4% (+4.5 percentage points QoQ) [2] - Q4 2025 selling and administrative expense ratio was 37.1% (-0.5 percentage points QoQ) [2] - Q4 2025 R&D expense ratio was 41.1% (+4 percentage points QoQ) [2] Future Outlook - For 2026, total revenue is projected to be between $6.2 billion and $6.4 billion, with a gross margin above 80% [3] - GAAP operating profit is expected to be between $700 million and $800 million, while non-GAAP operating profit is projected to be between $1.4 billion and $1.5 billion [3]